Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:17302568rdf:typepubmed:Citationlld:pubmed
pubmed-article:17302568lifeskim:mentionsumls-concept:C0030705lld:lifeskim
pubmed-article:17302568lifeskim:mentionsumls-concept:C0011065lld:lifeskim
pubmed-article:17302568lifeskim:mentionsumls-concept:C0153690lld:lifeskim
pubmed-article:17302568lifeskim:mentionsumls-concept:C0038952lld:lifeskim
pubmed-article:17302568lifeskim:mentionsumls-concept:C0040223lld:lifeskim
pubmed-article:17302568lifeskim:mentionsumls-concept:C1328504lld:lifeskim
pubmed-article:17302568lifeskim:mentionsumls-concept:C0237881lld:lifeskim
pubmed-article:17302568lifeskim:mentionsumls-concept:C0936012lld:lifeskim
pubmed-article:17302568lifeskim:mentionsumls-concept:C0868928lld:lifeskim
pubmed-article:17302568lifeskim:mentionsumls-concept:C0750502lld:lifeskim
pubmed-article:17302568pubmed:issue2lld:pubmed
pubmed-article:17302568pubmed:dateCreated2007-2-16lld:pubmed
pubmed-article:17302568pubmed:abstractTextMost of the metastatic diseases initially respond to maximum androgen blockade, but then relapse and lose response, and finally die. After relapse, the disease progresses in various courses. The present study was aimed to establish the predicting factors influencing the survival period of patients at prostate-specific antigen (PSA) relapse (entering the hormone refractory state).lld:pubmed
pubmed-article:17302568pubmed:languageenglld:pubmed
pubmed-article:17302568pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17302568pubmed:citationSubsetIMlld:pubmed
pubmed-article:17302568pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17302568pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17302568pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17302568pubmed:statusMEDLINElld:pubmed
pubmed-article:17302568pubmed:monthFeblld:pubmed
pubmed-article:17302568pubmed:issn0919-8172lld:pubmed
pubmed-article:17302568pubmed:authorpubmed-author:ShimazakiJunJlld:pubmed
pubmed-article:17302568pubmed:authorpubmed-author:NakatsuHiroom...lld:pubmed
pubmed-article:17302568pubmed:authorpubmed-author:MurakamiShino...lld:pubmed
pubmed-article:17302568pubmed:authorpubmed-author:ShimboMasakiMlld:pubmed
pubmed-article:17302568pubmed:authorpubmed-author:TomiokaSusumu...lld:pubmed
pubmed-article:17302568pubmed:authorpubmed-author:AmiyaYoshiyas...lld:pubmed
pubmed-article:17302568pubmed:issnTypePrintlld:pubmed
pubmed-article:17302568pubmed:volume14lld:pubmed
pubmed-article:17302568pubmed:ownerNLMlld:pubmed
pubmed-article:17302568pubmed:authorsCompleteYlld:pubmed
pubmed-article:17302568pubmed:pagination123-7lld:pubmed
pubmed-article:17302568pubmed:meshHeadingpubmed-meshheading:17302568...lld:pubmed
pubmed-article:17302568pubmed:meshHeadingpubmed-meshheading:17302568...lld:pubmed
pubmed-article:17302568pubmed:meshHeadingpubmed-meshheading:17302568...lld:pubmed
pubmed-article:17302568pubmed:meshHeadingpubmed-meshheading:17302568...lld:pubmed
pubmed-article:17302568pubmed:meshHeadingpubmed-meshheading:17302568...lld:pubmed
pubmed-article:17302568pubmed:meshHeadingpubmed-meshheading:17302568...lld:pubmed
pubmed-article:17302568pubmed:meshHeadingpubmed-meshheading:17302568...lld:pubmed
pubmed-article:17302568pubmed:meshHeadingpubmed-meshheading:17302568...lld:pubmed
pubmed-article:17302568pubmed:meshHeadingpubmed-meshheading:17302568...lld:pubmed
pubmed-article:17302568pubmed:meshHeadingpubmed-meshheading:17302568...lld:pubmed
pubmed-article:17302568pubmed:meshHeadingpubmed-meshheading:17302568...lld:pubmed
pubmed-article:17302568pubmed:meshHeadingpubmed-meshheading:17302568...lld:pubmed
pubmed-article:17302568pubmed:meshHeadingpubmed-meshheading:17302568...lld:pubmed
pubmed-article:17302568pubmed:meshHeadingpubmed-meshheading:17302568...lld:pubmed
pubmed-article:17302568pubmed:year2007lld:pubmed
pubmed-article:17302568pubmed:articleTitleSignificance of prostate-specific antigen-doubling time on survival of patients with hormone refractory prostate cancer and bone metastasis: analysis on 56 cases of cancer-specific death.lld:pubmed
pubmed-article:17302568pubmed:affiliationDepartment of Urology, Asahi General Hospital, Asahi, Japan.lld:pubmed
pubmed-article:17302568pubmed:publicationTypeJournal Articlelld:pubmed